A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy

Clifford, David B, Simpson, David M, Brown, Stephen, Moyle, Graeme, Brew, Bruce J, Conway, Brian, Tobias, Jeffrey K, Vanhove, Geertrui F, Fisher, Martin and for the NGX-4010 C119 Study Group, (2012) A randomized, double-blind, controlled study of NGX-4010, a capsaicin 8% dermal patch, for the treatment of painful HIV-associated distal sensory polyneuropathy. JAIDS Journal of Acquired Immune Deficiency Syndromes, 59 (2). pp. 126-133. ISSN 1944-7884

Full text not available from this repository.

Abstract

INTRODUCTION

Effective treatment of HIV-associated distal sensory polyneuropathy remains a significant unmet therapeutic need.

METHODS

In this randomized, double-blind, controlled study, patients with pain due to HIV-associated distal sensory polyneuropathy received a single 30-minute or 60-minute application of NGX-4010--a capsaicin 8% patch (n = 332)--or a low-dose capsaicin (0.04%) control patch (n = 162). The primary endpoint was the mean percent change from baseline in Numeric Pain Rating Scale score to weeks 2-12. Secondary endpoints included patient global impression of change at week 12.

RESULTS

Pain reduction was not significantly different between the total NGX-4010 group (-29.5%) and the total control group (-24.5%; P = 0.097). Greater pain reduction in the 60-minute (-30.0%) versus the 30-minute control group (-19.1%) prevented intended pooling of the control groups to test individual NGX-4010 treatment groups. No significant pain reduction was observed for the 30-minute NGX-4010 group compared with 30-minute control (-26.2% vs.-19.1%, respectively, P = 0.103). Pain reductions in the 60-minute NGX-4010 and control groups were comparable (-32.8% vs. -30.0%, respectively; P = 0.488). Posthoc nonparametric testing demonstrated significant differences favoring the total (P = 0.044) and 30-minute NGX-4010 groups (P = 0.035). Significantly, more patients in the total and 30-minute NGX-4010 group felt improved on the patient global impression of change versus control (67% vs. 55%, P = 0.011 and 65% vs. 45%, P = 0.006, respectively). Mild to moderate transient application site pain and erythema were the most common adverse events.

CONCLUSIONS

Although the primary endpoint analyses were not significant, trends toward pain improvement were observed after a single 30-minute NGX-4010 treatment.

Item Type: Article
Additional Information: Martin Fisher is part of the NGX-4010 C119 Study Group and not one of the principal authors
Schools and Departments: Brighton and Sussex Medical School > Brighton and Sussex Medical School
Subjects: R Medicine > RA Public aspects of medicine > RA0421 Public health. Hygiene. Preventive Medicine > RA0643 Communicable diseases and public health > RA0644 Individual diseases or groups of diseases, A-Z > RA0644.A25 AIDS. HIV infections
Related URLs:
Depositing User: Ellen Thomas
Date Deposited: 23 Dec 2013 12:22
Last Modified: 23 Dec 2013 12:22
URI: http://sro.sussex.ac.uk/id/eprint/47097
📧 Request an update